Screening for cervical cancer with high-risk human papillomavirus testing updated evidence report and systematic review for the us preventive services task force

JAMA - Journal of the American Medical Association

Volumn 320, Issue 7, 2018, Pages 687-705

  Melnikow, Joy ^b   Henderson, Jillian T ^a   Burda, Brittany U ^a   Senger, Caitlyn A ^a   Durbin, Shauna ^b   Weyrich, Meghan S ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; COLPOSCOPY; DISEASE SURVEILLANCE; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HEALTH SERVICE; HIGH RISK POPULATION; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TUMOR BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; ADULT; AGED; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH CARE QUALITY; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; AGED; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PROCESS ASSESSMENT (HEALTH CARE); UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85051972221     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.10400     Document Type: Article

References (61)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907. doi:10.1016/S0140-6736(07)61416-0
2. Ziegert C, Wentzensen N, Vinokurova S, et al. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene. 2003;22(25):3977-3984. doi:10.1038/sj.onc .1206629
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265. doi:10.1136/jcp.55.4.244
4. American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society website. https://www.cancer.org/research/cancer-facts -statistics/all-cancer-facts-figures/cancer-facts -figures-2016.html. Published 2016. Accessed June 27, 2017.
5. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23. doi:10 .1016/j.vaccine.2012.07.055
6. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819. doi:10 .1001/jama.297.8.813
7. Partridge EE, Abu-Rustum N, Giuliano A, et al; National Comprehensive Cancer Network. Cervical cancer screening. J Natl Compr Canc Netw. 2014; 12(3):333-341. doi:10.6004/jnccn.2014.0035
8. Surveillance, Epidemiology, and End Results (SEER). Cancer Stat Facts: cervical cancer. SEER website. https://seer.cancer.gov/statfacts/html/cervix.html. Published 2017. Accessed July 3, 2018.
9. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12): 880-891. doi:10.7326/0003-4819-156-12-201206190-00424
10. Huynh J, Howard M, Lytwyn A. Self-collection for vaginal human papillomavirus testing: systematic review of studies asking women their perceptions. J Low Genit Tract Dis. 2010;14(4):356-362. doi:10.1097/LGT.0b013e3181dc115b
11. Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ publication 11-05156-EF-1.
12. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388. doi:10.1371/journal.pmed.1002388
13. Ogilvie G, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320 (1):43-52. doi:10.1001/jama.2018.7464
14. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257. doi:10.1016/S1470-2045(09)70360-2
15. United Nation Development Programme. Human Development Report. New York, NY: United Nations; 2016.
16. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-434. doi:10.1016/S1470-2045 (08)70103-7
17. Harris RP, Helfand M, Woolf SH, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3)(suppl):21-35. doi:10.1016 /S0749-3797(01)00261-6
18. Wells GA, Shea BJ, O'Connell DPJ, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa Hospital Research Institute website. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 2014. Accessed June 27, 2017.
19. Cook DA, Mei W, Smith LW, et al. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968. doi:10.1186/s12885-015-1959-5
20. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501. doi:10.1093/jnci/djn065
21. Ogilvie GS, Krajden M, van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440-448. doi:10.1002/ijc.30454
22. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial). BMC Cancer. 2010;10:111. doi:10.1186 /1471-2407-10-111
23. Leinonen MK, Nieminen P, Lönnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012; 345:e7789. doi:10.1136/bmj.e7789
24. Zorzi M, Frayle H, Rizzi M, et al; Veneto HPV-Screening Working Group. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study. BJOG. 2017;24(10):1585-1593. doi:10 .1111/1471-0528.14575
25. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547-555. doi:10.1016 /S1470-2045(06)70731-8
26. Ronco G, Segnan N, Giorgi-Rossi P, et al; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765-774. doi:10.1093/jnci/djj209
27. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004; 110(1):94-101. doi:10.1002/ijc.20076
28. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88. doi: 10.1016/S1470-2045(11)70296-0
29. Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924. doi:10.1136/bmj.i4924
30. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer [published correction appears in N Engl J Med. 2008;359(15):1637]. N Engl J Med. 2007;357(16):1589-1597. doi:10.1056 /NEJMoa073204
31. Elfström KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014; 348:g130. doi:10.1136/bmj.g130
32. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer. 2008;18(4):743-748. doi:10.1111/j .1525-1438.2007.01113.x
33. Kitchener HC, Almonte M, Gilham C, et al; ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1-150. doi:10.3310/hta13510
34. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682. doi:10.1016/S1470-2045(09) 70156-1
35. Kitchener HC, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1-196. doi:10.3310/hta18230
36. Castle PE, Fetterman B, Poitras N, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol. 2011;117(3):650-656. doi:10.1097/AOG .0b013e318209da59
37. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice [published correction appears in Lancet Oncol. 2011;12(8):722]. Lancet Oncol. 2011;12(7):663-672. doi:10.1016/S1470-2045 (11)70145-0
38. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S56-S63. doi:10.1097/LGT.0b013e318285437b
39. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S28-S35. doi:10.1097 /LGT.0b013e318285423c
40. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8): dju153. doi:10.1093/jnci/dju153
41. Gage JC, Katki HA, Schiffman M, et al. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. Int J Cancer. 2015;136(7): 1665-1671. doi:10.1002/ijc.29143
42. Ibáñez R, Autonell J, Sardà M, et al. Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer. 2014;14:574. doi:10.1186/1471-2407-14-574
43. Petry KU, Luyten A, Scherbring S. Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol. 2013;128(2):282-287. doi:10.1016/j.ygyno .2012.10.017
44. Luyten A, Buttmann-Schweiger N, Luyten K, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014; 135(6):1408-1416. doi:10.1002/ijc.28783
45. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004; 111(12):1437-1443. doi:10.1111/j.1471-0528.2004 .00279.x
46. USPreventiveServicesTaskForce.USPreventive ServicesTaskForceProcedureManual.Rockville,MD:AgencyforHealthcareResearchandQuality;2015.
47. Ronco G, Dillner J, Elfström KM, et al; International HPV Screening Working Group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736 (13)62218-7
48. Castle PE, Kinney WK, Xue X, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. Ann Intern Med. 2018;168(1):20-29. doi:10.7326/M17-1609
49. Demarco M, Lorey TS, Fetterman B, et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. J Low Genit Tract Dis. 2017;21(4):261-267. doi:10.1097/LGT .0000000000000343
50. Gage JC, Hunt WC, Schiffman M, et al; New Mexico HPV Pap Registry Steering Committee. Similar risk patterns after cervical screening in two large U.S. populations: implications for clinical guidelines. Obstet Gynecol. 2016;128(6):1248-1257. doi:10.1097/AOG.0000000000001721
51. Coldman AJ, Gondara L, Smith LW, et al. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer. 2016;115(12):1487-1494. doi:10.1038/bjc.2016.368
52. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010;(6):CD001318.
53. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet. 2000;68(1):25-33. doi:10.1016/S0020-7292(99)00162-9
54. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2015;(9):CD008478.
55. Conner SN, Frey HA, Cahill AG, Macones GA, Colditz GA, Tuuli MG. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. Obstet Gynecol. 2014;123(4):752-761. doi:10.1097/AOG .0000000000000174
56. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10): 698-705. doi:10.7326/0003-4819-155-10-201111150-00377
57. Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M; Centers for Disease Control and Prevention (CDC). Vital signs: cervical cancer incidence, mortality, and screening-United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004-1009.
58. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132(10):2223-2236. doi:10.1002/ijc.27790
59. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health. 2013;104(2): e159-e166.
60. Singh GK, Williams SD, Siahpush M, Mulhollen A. Socioeconomic, rural-urban, and racial inequalities in US cancer mortality: part I-all cancers and lung cancer and part II-colorectal, prostate, breast, and cervical cancers. J Cancer Epidemiol. 2011;2011: 107497. doi:10.1155/2011/107497
61. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014; 120(13):2032-2038. doi:10.1002/cncr.28548